Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study

Brian Calingaert; Alicia W. Gilsenan; Catherine B. Johannes; James Bradley Layton; Allison Tse Kawai; CC Fuller; Alison Kawai; K Haynes; Kevin Coughlin; J Reynolds; R Hawrusik; C Horgin; Brian Calingaert; Kay Johannes; James Bradley Layton; A Peterson; N Praet; C Willame; E Yost; C Brannan; Cheryl N. McMahill-Walraven; M Guzman; A Jamal-allial; V Nair; RM Seals; FT Wang; M Selvan; Q Ma; R Platt; Alicia W. Gilsenan; J Brown

Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study

Fuller, CC., Kawai, A. T., Haynes, K., Coughlin, K., Reynolds, J., Hawrusik, R., Horgin, C., Calingaert, B., Johannes, C., Layton, J. B., Peterson, A., Praet, N., Willame, C., Yost, E., Brannan, C., McMahill-Walraven, C. N., Guzman, M., Jamal-allial, A., Nair, V., ... Brown, J. (2022). Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study. Pharmacoepidemiology and Drug Safety, 31(S2), 620.

Copy citation